

Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 8-K

HEMISPHERX BIOPHARMA INC
Form 8-K
October 15, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of report (Date of earliest
event reported):
October 15, 2009

HEMISPHERX BIOPHARMA, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware 0-27072 52-0845822
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)

1617 JFK Boulevard, Philadelphia, Pennsylvania, 19103
(Address of Principal Executive Offices, including Zip Code)

Registrant's telephone number, including area code: (215) 988-0080

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))

=====

Item 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a
Provision of the Code of Ethics.

On October 15, 2009, the Board of Directors of Hemispherx Biopharma, Inc. (the

Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 8-K

"Company"), upon the recommendation of the Audit Committee of the Board of Directors, approved amendments to the Company's Code of Ethics.

The principal amendments include broadening the Code's application to agents and consultants of the Company, the adoption of a regulatory compliance policy and the adoption of a policy for protection and use of Company computer technology for business purposes only. The amendments to the Code of Ethics are effective immediately. None of the amendments constituted a waiver of a provision of the Code of Ethics on behalf of the Company's Chief Executive Officer, Chief Financial Officer, Controller, or persons performing similar functions.

A copy of the amended Code of Ethics is available on the Company's Internet website at www.hemispherx.net. A copy will be mailed to any person, without charge, upon written request addressed to:

Corporate Secretary
Hemispherx Biopharma, Inc.
1617 JFK Boulevard
Suite 660
Philadelphia, Pennsylvania, 19103

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 15, 2009

HEMISPHERX BIOPHARMA, INC.

/s/ William A. Carter

William A. Carter, M.D.,
Chief Executive Officer